GBR 830, an anti-OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitis

2019214 citationsJournal Articlehybrid Open Access

Authors

Emma Guttman‐Yassky · Icahn School of Medicine at Mount Sinai

Ana B. Pavel · Icahn School of Medicine at Mount Sinai

Lisa Zhou · Icahn School of Medicine at Mount Sinai

Yeriel Estrada · Icahn School of Medicine at Mount Sinai

Ning Zhang · Icahn School of Medicine at Mount Sinai

Hui Xu · Icahn School of Medicine at Mount Sinai

Xiangyu Peng

Abstract

Two doses of GBR 830 administered 4 weeks apart were well tolerated and induced significant progressive tissue and clinical changes until day 71 (42 days after the last dose), highlighting the potential of OX40 targeting in patients with AD.

Topics & Keywords

Dermatology and Skin Diseases Asthma and respiratory diseases T-cell and B-cell Immunology

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Allergy and Clinical Immunology

Volume 144, Issue 2, pp. 482-493.e7

DOI: 10.1016/j.jaci.2018.11.053

Field-Weighted Citation Impact: 22.31